Beam Therapeutics Inc BEAM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
-
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
-
Shares of Beam Therapeutics Retreat After Updated Trial Data Disappoints
Trading Information
- Previous Close Price
- $24.39
- Day Range
- $24.21–25.48
- 52-Week Range
- $20.23–38.26
- Bid/Ask
- $24.50 / $24.56
- Shares Outstanding
- 103.29M
- Market Cap
- $2.53B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 197.79
- Price/Sales
- 16.15
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 540
- Website
- https://www.beamtx.com
Valuation
|
Metric
|
BEAM
|
|---|---|
Price/Earnings (Normalized) | 197.79 |
Price/Book Value | 2.36 |
Price/Sales | 16.15 |
Price/Cash Flow | — |
Price/Earnings
BEAM
Financial Strength
|
Metric
|
BEAM
|
|---|---|
Quick Ratio | 14.25 |
Current Ratio | 14.57 |
Interest Coverage | — |
Quick Ratio
BEAM
Profitability
|
Metric
|
BEAM
|
|---|---|
Return on Assets (Normalized) | −0.10% |
Return on Equity (Normalized) | −0.12% |
Return on Invested Capital (Normalized) | −3.11% |
Return on Assets
BEAM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>b<zXQ | LOCK|h@qc> | $128B | |||
| Moderna Inc
MRNA
| LOCK|^@b%QL | LOCK|ddX | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|p#TynC< | LOCK|V?<qm | $76B | |||
| argenx SE ADR
ARGX
| LOCK|TQ^&$Y? | LOCK|kf | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|RK$hjZL | LOCK|bp | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|b?%scL | LOCK|C<<q | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|t@Tl&t$j | LOCK|&l<Z | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|&@XDY$ | LOCK|&mV | $24B | |||
| Incyte Corp
INCY
| LOCK|^MmLyhY | LOCK|&ST | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|v&Ks>< | LOCK|$NT | $15B |
United States